Nicotine capture type smoking cessation medicine based on molecular configuration matching

By precisely matching nicotine molecules through a three-dimensional molecular cage structure, it blocks nicotine from entering the central nervous system and metabolizing and clearing it in the peripheral circulation, solving the problems of adverse reactions and high relapse rates of existing smoking cessation drugs, and providing a safe and efficient smoking cessation solution.

CN122272844APending Publication Date: 2026-06-26薛梁
0 Cites 0 Cited by

Patent Information

Application Number
CN202610558948.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-04-25
Publication Date
2026-06-26

AI Technical Summary

Technical Problem

Existing smoking cessation medications cannot prevent nicotine from entering the central nervous system at the source, resulting in strong withdrawal reactions, high relapse rates, and problems with adverse reactions and poor tolerability.

Method used

Three specific configurations of organic functional molecular materials are used to self-assemble into a three-dimensional molecular cage, which precisely matches nicotine molecules, blocks them from entering the central nervous system, and eliminates them through peripheral circulation metabolism, thus avoiding central invasion and adverse reactions.

Benefits of technology

It achieves specific capture and safe metabolic excretion of nicotine, reduces withdrawal reactions and relapse rates, improves patient tolerance, and is suitable for all types of nicotine-dependent populations.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses a nicotine capture type smoking cessation medicine composition based on molecular configuration matching, and belongs to the technical field of smoking cessation medicines. The medicine is prepared by self-assembling three organic functional molecules (each molecule has a specific configuration and is shown in Figure 2) screened by a molecular structure according to a specific molar ratio in a human physiological environment to form a three-dimensional molecular cage, and the molecular cage is accurately matched with a nicotine molecular chair-type conformation through an inner cavity configuration (the configuration after combination is shown in Figure 3), so that the nicotine molecular chair-type conformation is accurately matched with the nicotine molecular chair-type conformation, and the nicotine molecular chair-type conformation is accurately matched with the nicotine molecular chair-type conformation. According to the invention, nicotine molecules are specifically recognized and clathrated, the nicotine molecules are prevented from penetrating through a blood brain barrier to enter the brain by increasing the molecular weight and enhancing the polarity, and a nicotine addiction reward pathway is blocked from the source, so that the tobacco addiction and physiological dependence are eliminated. The medicine disclosed by the invention only plays a role in peripheral circulation, does not enter a central nervous system, does not act on cranial nerve receptors, and has no mental side effects and addiction, and the molecular cage-nicotine compound can be normally metabolized by a human body and is thoroughly discharged out of the body. According to the invention, accurate matching of molecular configurations is taken as core innovation, the mechanism is brand new, the safety is extremely high, withdrawal is mild, the relapse rate can be effectively reduced, and the application is suitable for various people dependent on nicotine and has extremely high clinical conversion value and patent protection value.
Need to check novelty before this filing date? Find Prior Art